Lercanidipina Aurobindo (Lercanidipine Hydrochloride)

Lercanidipine selectively inhibits L‑type calcium channels in vascular smooth‑muscle cells. By blocking calcium entry, it prevents muscle contraction, leading to vasodilation of peripheral arteries. This vasodilation decreases systemic vascular resistance, which in turn lowers arterial blood pressure.

The exact dosage is determined by the prescribing clinician based on the patient’s clinical condition, age, and response to therapy. In practice, clinicians often start with a low daily dose and may adjust it as needed, but the final regimen must always be set by a qualified healthcare professional.

Safety data for lercanidipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatments with their healthcare provider.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lercanidipine belongs to the dihydropyridine calcium‑channel blocker class, offering once‑daily dosing and a favorable side‑effect profile compared with some older agents. Compared with beta‑blockers, it primarily causes vasodilation rather than heart‑rate reduction, making it a useful alternative for patients who cannot tolerate beta‑blockers or ACE inhibitors.

Lercanidipina Aurobindo tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

The medication is taken orally, usually once daily. Patients should swallow the tablet whole with a full glass of water and may take it with or without food, as directed by their prescriber. Consistent timing each day helps maintain stable blood‑pressure control.

Serious adverse events, although rare, include angioedema, severe hypotension, myocardial infarction, and significant liver injury. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, chest pain, or signs of liver dysfunction such as jaundice.

Lercanidipine is contraindicated in patients with known hypersensitivity to the drug or any component of the formulation, as well as in individuals with severe hypotension, cardiogenic shock, or unstable heart failure. Clinicians should also exercise caution in patients with significant hepatic impairment.